Usted buscó: parenterally (Inglés - Maltés)

dose reduction for parenterally administered
sedazzjoni għal tul ta’ ħin.

do not administer orally or parenterally.
tapplikax oralment jew parenteralment.

are normally prescribed by a doctor to be administered parenterally.
huma normalment stabbiliti minn tabib biex ikunu amministrati minn ġenituri.

for caution on parenterally administered midazolam, see section 4.5.
sabiex tiġi eżerċitata kawtela meta midazolam jiġi mgħoti parenteralment, ara sezzjoni 4.5.

in case of insufficient feed intake, animals should be treated parenterally.
f’ każ ta ’ teħid insuffiċjenti ta ’ għalf, l- annimali għandhom jiġu ttrattati b’ mod parenterali.

hexacima must not be mixed with any other vaccines or other parenterally administered medicinal products.
hexacima m’għandux jitħallat ma’ kwalunkwe vaċċini jew mediċini oħra li jingħataw b’mod parenterali.

parenterally administered anidulafungin was effective against candida species in immunocompetent and immunocompromised mouse and rabbit models.
anidalfungin mogħti b’mod parenterali, kien effettiv kontra speċi ta’ candida f’mudelli ta’ ġrieden u fniek immunokompetenti u immunokompromessi.

parenterally administered iron preparations can cause hypersensitivity reactions including serious and potentially fatal anaphylactic/anaphylactoid reactions.
preparazzjonijiet li fihom ħadid li jingħataw b’mod parenterali jistgħu jikkawżaw reazzjonijiet ta’ sensittività eċċessiva li jinkludu reazzjonijiet anafilattiċi/anafilattojdi serji u potenzjalment fatali.

for caution on parenterally administered midazolam see section 4.5) and hmg-coa reductase inhibitors (simvastatin and lovastatin).
għal kawtela dwar midazolam mogħti b’ mod parenterali ara sezzjoni 4. 5) u impedituri ta 'l- enzima hmg- coa reductase (simvastatin u lovastatin).

in the event of overdose, appropriate supportive treatment (possibly given parenterally) should be initiated according to the patient’s clinical signs and symptoms.
f’każ ta’ doża eċċessiva, għandha tinbeda l-kura adattata ta’ sostenn (possibbilment b’mod parenterali) skond is-sinjali u s-sintomi kliniċi tal-pazjent.

these active substances include e. g. antiarrhythmics (amiodarone, bepridil, quinidine, systemic lidocaine), antihistamines (astemizole, terfenadine), ergot derivatives (e. g. dihydroergotamine, ergonovine, ergotamine, methylergonovine), gastrointestinal motility agents (cisapride), neuroleptics (pimozide, sertindole), sedatives/ hypnotics (triazolam, midazolam administered orally (for caution on parenterally administered midazolam, see section 4.5)) and hmg-coa reductase inhibitors (simvastatin and lovastatin) (see section 4.5).
dawn is- sustanzi attivi jinkludu e. ż. antiarritmiċi (amiodarone, bepridil, quinidine, lidocaine sistemiku), antistamini (astemizole, terfenadine), derivattivi ta ’ l- ergot (e. ż. dihydroergotamine, ergonovine, ergotamine, methylergonovine), aġenti tal- mobilità gastro- intestinali (cisapride), newrolettiċi (pimozide, sertindole), sedattivi/ ipnotiċi (triazolam, midazolam mogħti mill- ħalq (għal attenzjoni dwar midazolam li jingħata b’ mod parenterali, ara sezzjoni 4. 5)) u impedituri ta ’ l- hmg- coa reductase (simvastatin u lovastatin) (ara sezzjoni 4. 5).